Table 2.
Biochemical and haemodynamic values during each treatment phase
| Placebo | Amiloride | |
| Serum potassium (mmol/l) | 4.4 (0.4) | 4.8 (0.5)* |
| Serum urea (mmol/l) | 6.4 (1.5) | 7.9 (1.7) |
| Serum creatinine (μmol/l) | 103 (23) | 111 (26) |
| Baseline heart rate (beats/min) | 73 (8) | 73 (7) |
| Baseline blood pressure (mm Hg) | ||
| SBP | 134 (6) | 133 (4) |
| DBP | (73 )7 | 73 (8) |
| MAP | 93 (5) | 93 (5) |
| Acetylcholine blood pressure (mm Hg) | ||
| SBP | 134 (6) | 134 (4) |
| DBP | 75 (5) | 73 (4) |
| MAP | 94 (4) | 93 (2) |
| Sodium nitroprusside blood pressure (mm Hg) | ||
| SBP | 133 (8) | 133 (4) |
| DBP | 77 (4) | 74 (4) |
| MAP | 95 (4) | 94 (3) |
| NG-monomethyl-l-arginine blood pressure (mm Hg) | ||
| SBP | 132 (7) | 132 (6) |
| DBP | 75 (6) | 73 (4) |
| MAP | 93 (5) | 93 (2) |
| Angiotensin I blood pressure (mm Hg) | ||
| SBP | 134 (8) | 133 (5) |
| DBP | 75 (3) | 72 (5) |
| MAP | 95 (3) | 93 (4) |
| Angiotensin II blood pressure (mm Hg) | ||
| SBP | 132 (8) | 131 (8) |
| DBP | 73 (4) | 73 (5) |
| MAP | 94 (3) | 93 (4) |
*p<0.05 for difference between treatments.
DBP, diastolic blood pressure; MAP, mean arterial pressure; SBP, systolic blood pressure.